Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dantrolene for hyperthermia after subarachnoid hemorrhage
2007-003232-35Phase 3
Key facts
- Status
- Terminated
- Start
- Jul 2007
- Countries
- 1
- Sponsor
- Medical University of Vienna
- Modality
- Classical Binding Small Molecules → Small Molecules
- Drugs
- dantrolene
- Conditions
- hyperthermia
01
Overview
Phase 3, single-arm trial of dantrolene in hyperthermia, sponsored by Medical University of Vienna. Primary endpoint: Febrile episode assessment at fever onset. Started Jul 2007; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedSingle group
Dantrolene treatment
Single-group treatment of centrally mediated hyperthermia after subarachnoid hemorrhage with dantrolene.
03
Who it enrols
Adults aged 18 to 80 years who are neurosurgical patients after subarachnoid hemorrhage. Patients with evidence suggesting an active infection likely to cause fever are excluded.
04
Endpoints
Primary
Febrile episode assessment at fever onset
Beyond the preview
Go deeper on 2007-003232-35.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003232-35.